How to Become an Egg Donor: Requirements and Steps

Egg donation involves a multi-step process that typically spans two to three months from initial application to egg retrieval, though the timeline varies by clinic and program. You start with an application and screening phase, move into a period of hormone injections to stimulate your ovaries, and finish with a short outpatient procedure to collect the eggs. The process is more involved than many people expect, and understanding each stage before you apply helps you decide whether it is right for you.

Who Can Donate

Most egg donor programs require you to be between 21 and 34 years old, though some clinics accept donors as young as 18 or as old as 35. The age window exists because younger ovaries tend to respond better to stimulation medications and produce eggs with lower rates of chromosomal abnormalities. A large European study found the average age of egg donors across eleven countries was about 27, and the typical donor profile was a woman living with a partner who already had at least one child of her own.

Beyond age, the basic eligibility checklist at most programs includes:

BMI range: Most clinics want a body mass index between roughly 18 and 30, since extremes in either direction can affect how your ovaries respond to medication and increase procedural risk.
Non-smoker status: Active smoking disqualifies you at nearly every program, and many ask that you abstain from recreational drugs as well.
No major hereditary conditions: A personal or close family history of serious genetic disorders will typically rule you out, though mild or common conditions may not.
Reliable availability: You need to be able to attend frequent monitoring appointments over about two weeks, which means your schedule has to accommodate morning ultrasound and blood-draw visits, sometimes on short notice.

Programs also want to know your reproductive history. Having already had a successful pregnancy is considered a positive sign because it demonstrates that your reproductive system works, but it is not a hard requirement at every clinic. Some programs recruit college students who have never been pregnant.

What the Screening Process Involves

Screening is by far the longest part of becoming a donor. It is also where most applicants drop out or get turned away. The process generally has three layers: medical, genetic, and psychological.

The medical screening includes bloodwork to check your hormone levels, ovarian reserve testing (usually an ultrasound to count visible follicles on your ovaries and a blood test for AMH, the hormone that correlates with egg supply), and infectious disease panels. The U.S. Food and Drug Administration requires fertility programs to screen egg donors for a specific set of communicable diseases under federal tissue-donor regulations, and programs bear the cost of implementing those screening protocols.¹

Genetic screening has become increasingly thorough. Many programs now use expanded carrier screening panels that test for dozens or even hundreds of recessive genetic conditions at once. Donor screening organizations like Cryos International, for example, use bespoke panels to check gamete donors for carrier status across a wide array of conditions.² The goal is not to find “perfect” donors but to identify carrier risks that could combine with a recipient’s genetics to produce a child with a serious inherited condition.

Psychological Screening

Almost every reputable program requires a psychological evaluation. This is not a rubber stamp. Research on over 2,500 donor candidates found that a standardized psychological questionnaire and a clinical interview together were far more effective than either alone in determining who was a good fit for donation. Among candidates who scored within normal limits on the written questionnaire, about one in ten was still turned away after the clinical interview, usually for reasons like a concerning family psychiatric history, insufficient altruistic motivation, or signs of low reliability and commitment. On the flip side, about half of candidates whose questionnaire scores flagged potential issues were accepted after the interview revealed those concerns to be temporary or situational rather than stable problems.³

The interview typically covers your understanding of the process, your reasons for donating, how you feel about the possibility of biological children you will not raise, and whether you have a support system in place. Programs want to make sure you have thought through the emotional dimensions and are not making a purely impulsive decision.

The Hormone Stimulation Phase

Once you clear screening and are matched with a recipient (or assigned to a donor egg bank cycle), the medical phase begins. The goal is to get your ovaries to produce multiple mature eggs in a single cycle rather than the usual one.

You will give yourself daily injections of gonadotropins, which are hormones that stimulate your ovaries. These injections typically continue for about 10 to 14 days. During that time, you will visit the clinic every few days for blood draws and transvaginal ultrasounds so your doctor can monitor how many follicles are growing and how large they are getting. Dosages get adjusted based on your response.

Several different stimulation protocols exist, and research has found that the main approaches produce similar outcomes. A systematic review of randomized trials found little difference in the number of eggs retrieved or pregnancy rates among recipients whether donors used a GnRH antagonist protocol, a GnRH agonist protocol, or a progesterone-primed protocol.⁴ In practical terms, your clinic will choose a protocol based on their experience, your body’s hormone profile, and logistical factors. You do not usually need to advocate for a particular protocol yourself.

When monitoring shows that your follicles have reached the right size, you will take a “trigger shot” that prompts final egg maturation. The type of trigger matters for side effects, which we will get to shortly. Egg retrieval is then scheduled for roughly 34 to 36 hours after the trigger.

What Happens During Egg Retrieval

The retrieval itself is a short outpatient procedure, usually done under conscious sedation so you are comfortable but do not need general anesthesia. A thin needle is passed through the wall of the vagina under ultrasound guidance and into each ovarian follicle to aspirate the fluid and the egg inside it.⁵ The procedure takes about 15 to 30 minutes.

This technique has been the standard approach since it was developed in the late 1980s, when transvaginal ultrasound-guided retrieval replaced earlier surgical methods.⁶ It is far less invasive than the laparoscopic methods that preceded it, and serious complications during the procedure itself are uncommon. In a large review of over 4,000 donor cycles, complications directly related to the retrieval (mainly minor intra-abdominal bleeding) occurred in less than half a percent of cases, and only about 0.15% required surgical intervention.⁷

After the procedure, you will rest at the clinic for an hour or two and then go home. Most donors take the rest of the day off and resume normal activities within a day or two. A retrospective study of commercial donors in the U.S. found that most women ranked their pain as somewhere between minimal and moderate at all time points assessed.⁸

Risks and Side Effects Worth Knowing About

The most talked-about risk of egg donation is ovarian hyperstimulation syndrome, a condition where the ovaries overreact to the stimulation drugs and swell, causing bloating, nausea, and in severe cases fluid accumulation in the abdomen or chest. The good news is that the type of trigger shot used at the end of stimulation has a major effect on how severe OHSS gets, and clinics have gotten much better at managing this risk.

A large donor-reported survey found that the trigger medication makes a real difference. With a GnRH agonist trigger (often called a Lupron trigger), severe OHSS occurred only about 1% of the time when fewer than 30 eggs were retrieved. With an hCG trigger, severe OHSS rates were considerably higher: roughly 10 to 12% of cycles where 10 to 39 eggs were collected, climbing to 19% when 40 or more were retrieved.⁹ This is why many donor programs have shifted toward GnRH agonist triggers for their donors, particularly for high responders who produce large numbers of eggs.

That same study found that OHSS severity in a first donation cycle was highly predictive of what would happen in subsequent cycles: about 71% of donors who donated more than once reported the same degree of OHSS both times.⁹ If you had a rough experience with OHSS in your first cycle, that is useful information to weigh before agreeing to donate again.

In the large series of over 4,000 donor cycles mentioned earlier, moderate-to-severe OHSS occurred in 22 donors (under 1% of all cycles), all of them associated with hCG triggering.⁷ Half were managed as outpatients. Ovarian torsion, where the enlarged ovary twists on its blood supply, occurred in just one case in that entire series.

What About Long-Term Health Effects

This is the area where the evidence is genuinely thin, and it is worth being honest about that. Short-term risks like OHSS and procedural complications are well-documented because they happen right away and get tracked. Long-term effects are much harder to study because donors are young, healthy, and often lose contact with the programs after their donation is complete.

One concern that has been raised is whether the high-dose hormones used in ovarian stimulation could affect long-term breast cancer risk. The connection is biologically plausible because long-term hormone replacement therapy is a recognized risk factor for breast cancer. A commentary in the reproductive medicine literature described five individual cases of egg donors who developed breast cancer, four of them in their thirties, despite negative genetic testing results. The authors stressed that the absence of long-term follow-up studies of egg donors should not be interpreted as absence of risk, and called for better tracking and informed consent.¹⁰

To be clear, five cases are not evidence of a causal link. Breast cancer occurs in young women for many reasons. But the point is that no one can currently tell you with certainty that repeated ovarian stimulation has zero effect on long-term cancer risk, because the large, long-duration studies that would answer that question have not been done. This is something to ask your clinic about and factor into your decision, particularly if you are considering multiple donation cycles.

Compensation and the Ethics Around It

In the United States, egg donors are typically compensated in a range that the American Society for Reproductive Medicine has suggested falls between $5,000 and $10,000 per cycle. ASRM’s ethics committee has argued that payments above $10,000 per cycle risk unduly motivating prospective donors to downplay the physical risks or to underreport personal medical history for financial gain.¹¹ In practice, some agencies and private arrangements exceed this guideline, and compensation can vary based on the donor’s education, ethnicity, prior donation success, and geographic location.

Compensation frameworks differ wildly outside the U.S. Many European countries prohibit payment beyond reimbursement for expenses. A survey of donors across eleven European countries found that about half cited pure altruism as their primary motivation, about a third mentioned a mix of altruism and financial motivation, and roughly 11% cited purely financial reasons.¹² In contrast, a study of egg donors in India found that 72% named financial need as their primary reason for donating, with only one participant out of 25 citing a desire to help a childless couple as the main motivation.¹³

These differences reflect broader economic and regulatory contexts. The ethical tension is real: you want compensation to be fair given the time, discomfort, and risk involved, but you do not want it so high that it pressures women in financial distress to overlook their own health concerns. There is no globally agreed-upon answer to where that line sits, and the debate continues within the field.

Fresh Versus Frozen Egg Donation

When you donate, your eggs may go directly to a matched recipient (a “fresh” cycle) or be vitrified and banked for future use (a “frozen” cycle). The distinction matters for your experience as a donor.

In a fresh cycle, your hormone stimulation schedule is often synchronized with the recipient’s uterine preparation, which means your timeline is partly dictated by someone else’s body. Frozen egg banking has simplified logistics considerably and lowered costs per treatment cycle for recipients.¹⁴ For you as the donor, a frozen cycle can mean more flexibility in scheduling, since your stimulation does not need to align precisely with a specific recipient’s calendar.

Some programs have also explored double stimulation protocols, where a donor undergoes two stimulation cycles and two retrievals within the same menstrual cycle, compressing what would otherwise be two separate donation cycles into a shorter timeframe.¹⁵ This is not yet standard practice, but it is an example of how programs are experimenting with ways to make the process more efficient for both donors and recipients.

How Donors Feel About the Experience Afterward

One of the most useful things you can learn before deciding to donate is what other donors report in hindsight. The research here is encouraging, with some caveats.

A U.S. study that asked donors to look back on their first donation cycle found that most overestimated the psychological difficulty beforehand: their pre-donation risk awareness predicted a harder experience than they actually had. The majority reported satisfaction, though a minority attributed lasting physical or psychological concerns to the donation process.¹⁶

A Spanish follow-up study found that 93% of donors highlighted positive feelings about their donation and 97% said they would recommend donating to others. The negative aspects that some donors mentioned were mainly physical: injection discomfort, pain, and side effects of ovarian stimulation.¹⁷

Longer-term data from Sweden, where donors are followed 14 to 17 years after their donation under an open-identity system, found no differences in anxiety or depression symptoms between egg donors and sperm donors (who undergo no medical procedure), and the overwhelming majority remained satisfied with their decision. Only four out of all the oocyte donors in the study regretted donating. Interestingly, egg donors were more than twice as likely as sperm donors to feel that family and friends were proud of their donation, though sperm donors were more frequently satisfied with the financial compensation they received.¹⁸

These are reassuring findings, but they come with a built-in bias: donors who had negative experiences may be less likely to participate in follow-up surveys. The most honest summary is that the large majority of donors report positive feelings long after the fact, while a smaller group carries physical or emotional concerns they connect to the donation.

Anonymity and the Reality of Consumer DNA Testing

If you are considering egg donation, you should understand that anonymity is no longer guaranteed regardless of what your contract says. The explosion of direct-to-consumer genetic testing services has fundamentally changed the landscape. Donor-conceived individuals can now upload their DNA data and find biological relatives, including their egg or sperm donor, through database matching. This reality is challenging the longstanding assumptions of the fertility industry around donor anonymity.¹⁹

Several countries have already moved to open-identity donation systems that give donor-conceived people the right to learn their donor’s identity once they reach adulthood. Sweden, the UK, Australia, and others have abolished anonymous donation entirely. In the U.S., anonymous and known donation both exist, and the choice is typically made at the time of the contract. But even if you choose anonymous donation, a biological child conceived from your eggs could still find you through a DNA database decades from now.

This does not mean donor-conceived individuals will show up at your door. Many never search, and those who do often want medical history information or simply to know where they came from. But it is worth going into the process with your eyes open: true anonymity in the genomic era is a promise that technology has largely made unenforceable. Programs with good informed consent processes will tell you this upfront.

How Many Times You Can Donate

ASRM guidelines recommend a limit of six stimulated cycles per donor, though this is a guideline rather than a legal mandate in the U.S. The rationale is partly medical, to limit cumulative exposure to high-dose hormones, and partly ethical, to reduce the number of genetic half-siblings a single donor might produce across different families. In the European survey, about 55% of donors were donating for the first time, about 20% for the second, and about 13% for the third.²⁰ Repeat donation is common, but the data on OHSS recurrence mentioned earlier is relevant: your body’s response to stimulation tends to be consistent across cycles, so a difficult first cycle is a meaningful warning signal.

Some donors report that later cycles feel easier simply because they know what to expect, while others find the cumulative inconvenience harder to absorb alongside work and family obligations. There is no universal trajectory, but the repeat-donation decision should involve a real conversation with your medical team about how your body responded the previous time around, not just a willingness to go through it again.

1
PubMed. Economic cost for implementation of the U.S. Food and Drug Administration’s Code of Federal Regulations Title 21, Part 1271 in an egg donor program
2
PubMed Central. The use of expanded carrier screening of gamete donors
3
Human Reproduction. Psychological screening of gamete donors: sociodemographic factors and the complementary role of clinical interview beyond a psychopathological screening test
4
Human Reproduction Update. Ovarian stimulation for oocyte donation: a systematic review and meta-analysis
5
PubMed. Optimal oocyte retrieval and embryo transfer techniques: where we are and how we got here
6
PubMed. Transvaginal recovery of oocytes for in vitro fertilization using vaginal ultrasound
7
PubMed. Complications related to ovarian stimulation and oocyte retrieval in 4052 oocyte donor cycles
8
PubMed. Perception of pain and the oocyte donor experience: a retrospective analysis of commercial US donors
9
PubMed Central. Egg donor self-reports of ovarian hyperstimulation syndrome: severity by trigger type, oocytes retrieved, and prior history
10
PubMed. Long-term breast cancer risk following ovarian stimulation in young egg donors: a call for follow-up, research and informed consent
11
Medicolegal and Bioethics. Egg donation compensation: ethical and legal challenges
12
Human Reproduction. Socio-demographic and fertility-related characteristics and motivations of oocyte donors in eleven European countries
13
PubMed Central. Indian egg donors’ characteristics, motivations and feelings towards the recipient and resultant child
14
Current Opinion in Endocrinology, Diabetes and Obesity. Fresh versus cryopreserved oocyte donation
15
PubMed Central. Unlocking new horizons in egg donation: clinical and logistical benefits of double ovarian stimulation
16
PubMed. Looking back: egg donors’ retrospective evaluations of their motivations, expectations, and experiences during their first donation cycle
17
PubMed. A follow-up study of the long-term satisfaction, reproductive experiences, and self-reported health status of oocyte donors in Spain
18
PubMed. Long-term follow-up of mental health and satisfaction in a Swedish sample of sperm and egg donors after open-identity donation
19
Family Court Review. Establishing Identity: How Direct‐to‐Consumer Genetic Testing Challenges the Assumption of Donor Anonymity
20
PubMed. Socio-demographic and fertility-related characteristics and motivations of oocyte donors in eleven European countries